+69.1%
ASTS vs MRNA
+444.4%
-375.3%
-60.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.6% | -3.4% | -2.2% | -5.4% |
| 7D | 0.0% | -10.1% | +10.1% | +0.7% |
| 30D | -9.2% | +126.7% | -136.0% | -19.8% |
| 3M | -29.6% | +184.1% | -213.8% | -44.7% |
| 6M | -30.5% | +143.3% | -173.7% | -41.6% |
| YTD | -14.1% | +359.9% | -373.9% | -47.1% |
| 1Y | +69.1% | +454.2% | -385.1% | -1.4% |
| All | +69.1% | +444.4% | -375.3% | -1.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling